#VisualAbstract: Pembrolizumab Increases Survival in Early-Stage Triple-Negative Breast Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
The post #VisualAbstract: Pembrolizumab Increases Survival in Early-Stage Triple-Negative Breast Cancer first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
‘Kris is still saving lives,’ says twin of late breast cancer campaigner
Maren Sheldon says her sister Kris – founder of charity Coppafeel – was a “beacon of hope” for many people.
Nvidia’s buyers, Boeing’s strike, Elon Musk and Bernie Sanders on Ozempic: Business news roundup
When Nvidia (NVDA) reported $30 billion in revenue in its second-quarter earnings results, the AI chipmaker disclosed that almost half of that came from only four customers. Read more…
Cognitive behavioral therapy program aids insomnia in breast cancer survivors
An in-home, voice-activated cognitive behavioral therapy (CBT) program improves insomnia symptoms among breast cancer survivors, according to a study published online Sept. 24 in JAMA Network Open.
Strategy to combat breast cancer involves two-pronged attack on enzyme that ‘feeds’ tumor
A study led by Brazilian researchers and reported in an article published in the journal Nature Communications proposes that simultaneously targeting the enzyme glutaminase and the protein HuR, both of which are essential to tumor progression, may be effective in treating breast cancer.
James Corden says Ozempic ‘didn’t really work’ for him for one big reason
During a recent episode of his “This Life of Mine” podcast, James Corden opened up about trying the medication for weight-loss and explained why it “didn’t really work” for him.
Semaglutide a Potential Treatment Option for OUD?
Semaglutide was linked to a significantly lower risk of overdose than other antidiabetic drugs in patients with type 2 diabetes and opioid use disorder. Medscape Medical News
Weight-loss surgery may preserve kidney health more effectively than GLP-1 drugs
The Data Are Clear: Patients Regain Weight After Stopping GLP-1 Drugs
(MedPage Today) — This story is part of a series called “Ozempic: Weighing the Risks and Benefits.” It was produced in part through a grant from the NIHCM Foundation.
Looking at the data from clinical trials of new GLP-1 agonists, it’s clear…
GLP-1 Agent May Hold Opioid Use Disorder Benefit
(MedPage Today) — Semaglutide (Ozempic, Wegovy) may help reduce the risk of an opioid overdose in certain people, an emulation target trial suggested.
Over a 1-year follow-up, people with comorbid type 2 diabetes and opioid use disorder (OUD…